Skip to main content

Table 2 Coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA cases

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Variables

MPA(n = 55)

LA(n = 76)

p

Single alteration

  

0.028*

 EGFR +

40(72.7%)

41(53.9%)

 

 ROS1 +

2(3.6%)

0

 

 EML4-ALK+

1(1.8%)

1(1.3%)

 

Double alteration

  

0.043*

 EGFR+; ROS1+

2(3.6%)

1(1.3%)

 

 ROS1+; EML4-ALK+

2(3.6%)

0

 

No alteration

  

0.001**

 EGFR-; ROS1-; EML4-ALK-

8(14.5%)

33(43.5%)

 
  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, EGFR- EGFR wild type, ROS1+ ROS1 fusion, ROS1- no ROS1 fusion, EML4-ALK+ EML4-ALK fusion, EML4-ALK- no EML4-ALK fusion
  2. *p<0.05; **p<0.01 compared with LA